{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:12:41Z","timestamp":1749010361231,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Shenzhen Medical Research Fund","award":["A2302009"],"award-info":[{"award-number":["A2302009"]}]},{"name":"the Shenzhen Science and Technology Innovation Commission, China","award":["JCYJ20210324114212035"],"award-info":[{"award-number":["JCYJ20210324114212035"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82073019"],"award-info":[{"award-number":["82073019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Div"],"DOI":"10.1186\/s13008-025-00151-3","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:44:19Z","timestamp":1748969059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UXT enhances melanoma proliferation, migration, and invasion through modulation of the P53 signaling pathway"],"prefix":"10.1186","volume":"20","author":[{"given":"Kaifen","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingqian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"151_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"151_CR2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","volume":"402","author":"GV Long","year":"2023","unstructured":"Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet Lond Engl. 2023;402:485\u2013502.","journal-title":"Lancet Lond Engl"},{"key":"151_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C. Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther. 2021;6:424.","journal-title":"Signal Transduct Target Ther"},{"key":"151_CR4","doi-asserted-by":"crossref","unstructured":"P H, S M, Z W, J X, X F, Y T. UXT at the crossroads of cell death, immunity and neurodegenerative diseases. Front Oncol [Internet]. 2023 [cited 2024 Dec 22];13. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37152054\/","DOI":"10.3389\/fonc.2023.1179947"},{"key":"151_CR5","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.2217\/fon-2022-0582","volume":"18","author":"Z Wang","year":"2022","unstructured":"Wang Z, Mo S, Han P, Liu L, Liu Z, Fu X, et al. The role of UXT in tumors and prospects for its application in hepatocellular carcinoma. Future Oncol Lond Engl. 2022;18:3335\u201348.","journal-title":"Future Oncol Lond Engl"},{"key":"151_CR6","doi-asserted-by":"publisher","first-page":"153808","DOI":"10.1016\/j.prp.2022.153808","volume":"232","author":"H Zhao","year":"2022","unstructured":"Zhao H, Chen C, Yang C, Mo S, Zhao H, Tian Y. Prefoldin and prefoldin-like complex subunits as predictive biomarkers for hepatocellular carcinoma immunotherapy. Pathol Res Pract. 2022;232:153808.","journal-title":"Pathol Res Pract"},{"key":"151_CR7","doi-asserted-by":"publisher","first-page":"110188","DOI":"10.1016\/j.cellsig.2021.110188","volume":"90","author":"X-C Hu","year":"2022","unstructured":"Hu X-C, Chu J, Zhou Y, Li C-C, Zhou G-J, Jiang G-Q. HOXD9 transcriptionally induced UXT facilitate breast cancer progression via epigenetic modification of RND3. Cell Signal. 2022;90:110188.","journal-title":"Cell Signal"},{"key":"151_CR8","first-page":"462","volume":"7","author":"J Yin","year":"2017","unstructured":"Yin J, Luo W, Zeng X, Zeng L, Li Z, Deng X, et al. UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer. Am J Cancer Res. 2017;7:462\u201372.","journal-title":"Am J Cancer Res"},{"key":"151_CR9","doi-asserted-by":"publisher","first-page":"17584","DOI":"10.18632\/oncotarget.3770","volume":"6","author":"M Qi","year":"2015","unstructured":"Qi M, Ganapathy S, Zeng W, Zhang J, Little JB, Yuan Z-M. UXT, a novel MDMX-binding protein, promotes Glycolysis by mitigating p53-mediated restriction of NF-\u03baB activity. Oncotarget. 2015;6:17584\u201393.","journal-title":"Oncotarget"},{"key":"151_CR10","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1158\/0008-5472.CAN-08-3738","volume":"69","author":"JC Nwachukwu","year":"2009","unstructured":"Nwachukwu JC, Mita P, Ruoff R, Ha S, Wang Q, Huang SJ, et al. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res. 2009;69:3140\u20137.","journal-title":"Cancer Res"},{"key":"151_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.18632\/oncotarget.26573","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Schafler ED, Thomas PA, Ha S, David G, Adney E, et al. Prostate-specific loss of UXT promotes cancer progression. Oncotarget. 2019;10:707\u201316.","journal-title":"Oncotarget"},{"key":"151_CR12","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1242\/jcs.185546","volume":"129","author":"S-K Su","year":"2016","unstructured":"Su S-K, Li C-Y, Lei P-J, Wang X, Zhao Q-Y, Cai Y, et al. The EZH1-SUZ12 complex positively regulates the transcription of NF-\u03baB target genes through interaction with UXT. J Cell Sci. 2016;129:2343\u201353.","journal-title":"J Cell Sci"},{"key":"151_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.omto.2021.12.008","volume":"24","author":"Z-F Huang","year":"2022","unstructured":"Huang Z-F, Tang Y-L, Shen Z-L, Yang K-Y, Gao K. UXT, a novel DNMT3b-binding protein, promotes breast cancer progression via negatively modulating LncRNA MEG3\/p53 axis. Mol Ther Oncolytics. 2022;24:497\u2013506.","journal-title":"Mol Ther Oncolytics"},{"key":"151_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13075-023-03037-3","volume":"25","author":"J Zhao","year":"2023","unstructured":"Zhao J, Li C, Qin T, Jin Y, He R, Sun Y, et al. Mechanical overloading-induced miR-325-3p reduction promoted chondrocyte senescence and exacerbated facet joint degeneration. Arthritis Res Ther. 2023;25:54.","journal-title":"Arthritis Res Ther"},{"key":"151_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.imbio.2014.08.010","volume":"220","author":"E Odkhuu","year":"2015","unstructured":"Odkhuu E, Mendjargal A, Koide N, Naiki Y, Komatsu T, Yokochi T. Lipopolysaccharide downregulates the expression of p53 through activation of MDM2 and enhances activation of nuclear factor-kappa B. Immunobiology. 2015;220:136\u201341.","journal-title":"Immunobiology"},{"key":"151_CR16","doi-asserted-by":"publisher","first-page":"eaao3003","DOI":"10.1126\/scitranslmed.aao3003","volume":"10","author":"LA Carvajal","year":"2018","unstructured":"Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, et al. Dual Inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018;10:eaao3003.","journal-title":"Sci Transl Med"},{"key":"151_CR17","doi-asserted-by":"publisher","first-page":"11656","DOI":"10.3390\/ijms231911656","volume":"23","author":"N Sabag","year":"2022","unstructured":"Sabag N, Yakobson A, Retchkiman M, Silberstein E. Novel biomarkers and therapeutic targets for melanoma. Int J Mol Sci. 2022;23:11656.","journal-title":"Int J Mol Sci"},{"key":"151_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","volume":"41","author":"J Lazaroff","year":"2023","unstructured":"Lazaroff J, Bolotin D. Targeted therapy and immunotherapy in melanoma. Dermatol Clin. 2023;41:65\u201377.","journal-title":"Dermatol Clin"},{"key":"151_CR19","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/biom12121874","volume":"12","author":"C Li","year":"2022","unstructured":"Li C, Kuai L, Cui R, Miao X. Melanogenesis and the targeted therapy of melanoma. Biomolecules. 2022;12:1874.","journal-title":"Biomolecules"},{"key":"151_CR20","unstructured":"Kh NS-M, Pc K, Ge T. S. UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells. J Cell Biochem [Internet]. 2017 [cited 2024 Dec 22];118. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28106301\/"},{"key":"151_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3389\/fonc.2020.00784","volume":"10","author":"MP Foschini","year":"2020","unstructured":"Foschini MP, Morandi L, Sanchez AM, Santoro A, Mul\u00e8 A, Zannoni GF, et al. Methylation profile of X-Chromosome-Related genes in male breast cancer. Front Oncol. 2020;10:784.","journal-title":"Front Oncol"},{"key":"151_CR22","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1158\/0008-5472.CAN-15-0563","volume":"75","author":"X Wang","year":"2015","unstructured":"Wang X, Simpson ER, Brown KA. p53: protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 2015;75:5001\u20137.","journal-title":"Cancer Res"},{"key":"151_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, et al. Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol OncolJ Hematol Oncol. 2021;14:157.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"151_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8:92.","journal-title":"Signal Transduct Target Ther"},{"key":"151_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41401-021-00752-y","volume":"43","author":"L-W Ren","year":"2022","unstructured":"Ren L-W, Li W, Zheng X-J, Liu J-Y, Yang Y-H, Li S, et al. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. Acta Pharmacol Sin. 2022;43:194\u2013208.","journal-title":"Acta Pharmacol Sin"},{"key":"151_CR26","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41418-020-0528-x","volume":"27","author":"Y Li","year":"2020","unstructured":"Li Y, Cao Y, Xiao J, Shang J, Tan Q, Ping F, et al. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia\/reperfusion-induced acute lung injury. Cell Death Differ. 2020;27:2635\u201350.","journal-title":"Cell Death Differ"},{"key":"151_CR27","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/s41388-020-1179-6","volume":"39","author":"Y Li","year":"2020","unstructured":"Li Y, Zhou Y, Li B, Chen F, Shen W, Lu Y, et al. WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5-MDM2-p53 pathway. Oncogene. 2020;39:2741\u201355.","journal-title":"Oncogene"},{"key":"151_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/bjc.2017.433","volume":"118","author":"C-E Wu","year":"2018","unstructured":"Wu C-E, Esfandiari A, Ho Y-H, Wang N, Mahdi AK, Aptullahoglu E, et al. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br J Cancer. 2018;118:495\u2013508.","journal-title":"Br J Cancer"},{"key":"151_CR29","doi-asserted-by":"crossref","unstructured":"Maietta I, Viscusi E, Laudati S, Iannaci G, D\u2019Antonio A, Melillo RM et al. Targeting the p90RSK\/MDM2\/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer. Cells [Internet]. 2024 [cited 2024 Dec 24];13:1546. Available from: https:\/\/www.mdpi.com\/2073-4409\/13\/18\/1546","DOI":"10.3390\/cells13181546"},{"key":"151_CR30","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1158\/1078-0432.CCR-19-1895","volume":"26","author":"RL Shattuck-Brandt","year":"2020","unstructured":"Shattuck-Brandt RL, Chen S-C, Murray E, Johnson CA, Crandall H, O\u2019Neal JF, et al. Metastatic melanoma Patient-Derived xenografts respond to MDM2 Inhibition as a single agent or in combination with BRAF\/MEK Inhibition. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:3803\u201318.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"151_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jnci\/djt003","volume":"105","author":"AA Dar","year":"2013","unstructured":"Dar AA, Majid S, Rittsteuer C, de Semir D, Bezrookove V, Tong S, et al. The role of miR-18b in MDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst. 2013;105:433\u201342.","journal-title":"J Natl Cancer Inst"},{"key":"151_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","volume":"15","author":"H Zhu","year":"2022","unstructured":"Zhu H, Gao H, Ji Y, Zhou Q, Du Z, Tian L, et al. Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials. J Hematol OncolJ Hematol Oncol. 2022;15:91.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"151_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1290\/0505029R.1","volume":"41","author":"F-L Min","year":"2005","unstructured":"Min F-L, Zhang H, Li W-J, Gao Q-X, Zhou G-M. Effect of exogenous wild-type p53 on melanoma cell death pathways induced by irradiation at different linear energy transfer. Vitro Cell Dev Biol Anim. 2005;41:284\u20138.","journal-title":"Vitro Cell Dev Biol Anim"},{"key":"151_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1471-2407-11-203","volume":"11","author":"KA Avery-Kiejda","year":"2011","unstructured":"Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and May contribute to proliferation. BMC Cancer. 2011;11:203.","journal-title":"BMC Cancer"},{"key":"151_CR35","unstructured":"Analysis. of TP53 mutation status in human cancer cell lines: a reassessment - PubMed [Internet]. [cited 2024 Dec 22]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24700732\/"},{"key":"151_CR36","first-page":"5278","volume":"60","author":"L Girnita","year":"2000","unstructured":"Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, Dricu A, et al. Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res. 2000;60:5278\u201383.","journal-title":"Cancer Res"},{"key":"151_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4149\/neo_2010_04_316","volume":"57","author":"K Rudolf","year":"2010","unstructured":"Rudolf K, Cervinka M, Rudolf E. Dual Inhibition of topoisomerases enhances apoptosis in melanoma cells. Neoplasma. 2010;57:316\u201324.","journal-title":"Neoplasma"},{"key":"151_CR38","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.gendis.2023.06.009","volume":"11","author":"Y Xie","year":"2024","unstructured":"Xie Y, Hou R, Hartman KL, Jiang J, Wu Z, Li W. JW-1-283 inhibits melanoma tumor growth via stabilization of the p53 pathway. Genes Dis. 2024;11:101036.","journal-title":"Genes Dis"},{"key":"151_CR39","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.3390\/ijms20164019","volume":"20","author":"B Besztercei","year":"2019","unstructured":"Besztercei B, Vancsik T, Benedek A, Major E, Thomas MJ, Schvarcz CA, et al. Stress-Induced, p53-Mediated tumor growth Inhibition of melanoma by modulated electrohyperthermia in mouse models without major Immunogenic effects. Int J Mol Sci. 2019;20:4019.","journal-title":"Int J Mol Sci"},{"key":"151_CR40","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/jid.2014.152","volume":"134","author":"Z Jian","year":"2014","unstructured":"Jian Z, Li K, Song P, Zhu G, Zhu L, Cui T, et al. Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo. J Invest Dermatol. 2014;134:2221\u201330.","journal-title":"J Invest Dermatol"},{"key":"151_CR41","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ijc.32756","volume":"147","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Huang Z, Su J, Li J, Zhao S, Wu L, et al. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer. 2020;147:139\u201351.","journal-title":"Int J Cancer"},{"key":"151_CR42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1535-7163.MCT-10-0581","volume":"10","author":"H Wang","year":"2011","unstructured":"Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011;10:69\u201379.","journal-title":"Mol Cancer Ther"}],"container-title":["Cell Division"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-025-00151-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13008-025-00151-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-025-00151-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T16:44:21Z","timestamp":1748969061000},"score":1,"resource":{"primary":{"URL":"https:\/\/celldiv.biomedcentral.com\/articles\/10.1186\/s13008-025-00151-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1186\/s13008-025-00151-3","relation":{},"ISSN":["1747-1028"],"issn-type":[{"value":"1747-1028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests. The authors declare that the concepts and information presented in this paper are based on research and are not commercially available. There are no conflicts to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}